West Chester, PA, United States
West Chester, PA, United States

Cephalon, Inc. is a U.S. biopharmaceutical company co-founded in 1987 by Dr. Frank Baldino, Jr., a pharmacologist and former scientist with the DuPont Company, who served as the company's chairman and chief executive officer until his death in December 2010. The company's name comes from the adjective "cephalic" meaning "related to the head or brain," and it was established primarily to pursue treatments for neurodegenerative diseases.Sales revenues reached $2.8 billion in 2010, ranking Cephalon among the leading biopharmaceutical companies in the world. In 2006, industry publication MedAd News named the company one of the ten most respected biotechnology firms in the world. Cephalon employs more than 3,700.Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006.On 2 May 2011, Teva announced its acquisition of Cephalon. Wikipedia.


Time filter

Source Type

Patent
Cephalon Inc. | Date: 2016-11-23

Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.


Patent
Cephalon Inc. | Date: 2016-10-13

The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.


Patent
Cephalon Inc. | Date: 2016-09-16

Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohns disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.


Patent
Cephalon Inc., University of Hawaii at Manoa and University of Utah | Date: 2016-10-14

Compounds of formula II are described: wherein D, n, R_(a), R_(b), and R_(c )are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.


Patent
Cephalon Inc. | Date: 2017-03-01

The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.


Patent
Cephalon Inc. | Date: 2017-04-05

Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.


Patent
Cephalon Inc. | Date: 2017-02-06

The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.


The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.


Patent
Cephalon Inc. and Brusselle | Date: 2017-07-19

Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising: 1) identifying a patient having moderate to severe eosinophilic asthma, wherein the patients symptoms are inadequately controlled with a current asthma therapeutic and wherein the patients blood eosinophil levels are equal to or greater than 400/L.; and 2) administering to said patient a therapeutically effective dose of reslizumab.


Patent
Cephalon Inc. | Date: 2016-06-17

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

Loading Cephalon Inc. collaborators
Loading Cephalon Inc. collaborators